oral squamous cell carcinoma (Cancer)
Information
- Disease name
- oral squamous cell carcinoma
- Disease ID
- DOID:0050866
- Description
- "An oral cavity cancer that has_material_basis_in squamous cells." [url:http\://en.wikipedia.org/wiki/Squamous-cell_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04649476 | Active, not recruiting | Phase 2 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma | March 22, 2021 | August 10, 2024 |
| NCT05551117 | Active, not recruiting | Phase 2 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | June 13, 2023 | May 2027 |
| NCT04137627 | Completed | Phase 3 | Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma | July 4, 2017 | December 18, 2018 |
| NCT03026361 | Completed | Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity | January 2010 | December 2014 | |
| NCT03502148 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma | June 19, 2018 | May 6, 2020 |
| NCT03554967 | Completed | Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma | July 2, 2018 | June 17, 2019 | |
| NCT04413214 | Completed | Phase 1 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | December 20, 2019 | December 30, 2022 |
| NCT05049408 | Completed | Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer | February 17, 2011 | December 7, 2016 | |
| NCT05455632 | Completed | Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery | June 1, 2022 | April 30, 2023 | |
| NCT05708209 | Completed | The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124 | November 1, 2022 | January 1, 2023 | |
| NCT05821179 | Completed | Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma | January 1, 2022 | February 25, 2023 | |
| NCT06438939 | Not yet recruiting | N/A | NBI for Early Diagnosis of OPMD/OSCC | September 30, 2024 | December 31, 2026 |
| NCT05806073 | Not yet recruiting | N/A | Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma | April 2023 | December 2026 |
| NCT06130007 | Not yet recruiting | Phase 2 | A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. | November 25, 2023 | October 25, 2024 |
| NCT05803915 | Not yet recruiting | Phase 2 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | May 1, 2023 | March 10, 2026 |
| NCT06055868 | Not yet recruiting | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | November 30, 2024 | November 30, 2029 | |
| NCT06174428 | Not yet recruiting | Validity of Viome's Oral/Throat Cancer Test | September 2024 | December 2026 | |
| NCT05125055 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | October 1, 2021 | December 30, 2026 |
| NCT05451303 | Recruiting | Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | May 27, 2022 | December 2025 | |
| NCT06321003 | Recruiting | SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography | March 13, 2024 | April 1, 2027 | |
| NCT05791149 | Recruiting | N/A | Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity | March 3, 2022 | October 2023 |
| NCT04718415 | Recruiting | Phase 2 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | January 23, 2021 | May 1, 2026 |
| NCT05024383 | Recruiting | N/A | Dissecting the Heterogeneity of Oral Cancer Pain | September 30, 2021 | December 2025 |
| NCT06258811 | Recruiting | Phase 3 | Neoadjuvant Immunochemotherapy for LAOSCC | February 20, 2024 | December 30, 2028 |
| NCT05069857 | Recruiting | Phase 2 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | September 1, 2021 | June 30, 2028 |
| NCT05098119 | Recruiting | Phase 2 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | September 16, 2021 | September 16, 2028 |
| NCT06336941 | Recruiting | N/A | "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON) | June 7, 2018 | December 31, 2030 |
| NCT05719779 | Recruiting | N/A | Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer. | February 3, 2023 | June 30, 2025 |
| NCT05766150 | Recruiting | Oral Microbioma and Oral Malignant Disease | December 1, 2021 | December 2024 | |
| NCT05798793 | Recruiting | Phase 3 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma | November 21, 2023 | October 1, 2026 |
| NCT05862168 | Recruiting | Phase 2 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | May 8, 2023 | June 30, 2028 |
| NCT05872880 | Recruiting | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | April 1, 2022 | September 2026 | |
| NCT05893888 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma | October 16, 2023 | October 2026 |
| NCT05902455 | Recruiting | Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis | May 25, 2021 | June 2025 | |
| NCT05927220 | Recruiting | WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA | July 3, 2023 | November 30, 2023 | |
| NCT06009861 | Recruiting | Phase 2 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | June 27, 2023 | August 31, 2027 |
| NCT06016400 | Recruiting | Phase 2/Phase 3 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | June 14, 2021 | April 30, 2024 |
| NCT06031337 | Recruiting | Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study | September 3, 2023 | December 1, 2023 | |
| NCT05611463 | Recruiting | Phase 2 | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients | June 2, 2020 | June 2, 2023 |
| NCT01587573 | Unknown status | Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer | April 2012 | December 2018 | |
| NCT02748707 | Unknown status | Phase 2 | Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study | August 18, 2015 | April 2023 |
| NCT01334320 | Unknown status | N/A | Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma | April 2011 | December 2021 |
| NCT03345966 | Unknown status | N/A | Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study | December 1, 2017 | November 2019 |
| NCT03418454 | Unknown status | The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw | December 14, 2017 | December 31, 2021 | |
| NCT03619304 | Unknown status | N/A | Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line | September 1, 2019 | July 17, 2020 |
| NCT04367909 | Unknown status | Phase 2 | A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma | June 21, 2020 | December 1, 2022 |
| NCT05150509 | Unknown status | Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy | December 15, 2020 | March 30, 2022 | |
| NCT01772706 | Unknown status | N/A | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer | October 30, 2008 | March 2021 |
| NCT04543266 | Unknown status | Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning | September 7, 2020 | December 31, 2023 | |
| NCT01987934 | Unknown status | Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma | June 2013 | December 2013 | |
| NCT02739204 | Unknown status | Phase 2 | Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma | November 2013 | December 2017 |
- Disase is a (Disease Ontology)
- DOID:8618
- Cross Reference ID (Disease Ontology)
- GARD:7263
- Exact Synonym (Disease Ontology)
- mouth squamous cell carcinoma